

COPY


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Agrawal	GROUP:	1635
SERIAL NO.:	09/412,947	EXAMINER:	J. Epps
DOCKET NO.:	HYZ-050CP2 (47508.446)		
FILING DATE:	October 5, 1999		
TITLE	MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND METHODS OF THEIR USE		

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being as first class mail with sufficient postage in an envelope addressed to **Box AF**, Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

17 Oct 2001
Date


Stephanie R. Johnson

BOX AF
Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. § 1.97, Applicants and their legal representatives hereby make of record the following references which are known by them and considered warranting disclosure under 37 C.F.R. § 1.56. The best available copies of all the references cited in the attached PTO Form 1449, except those listed below, are submitted herewith.

The following references are submitted as appendices to the Amendment filed herewith.

- Milner et al. (1997) "Selecting Effective Antisense Reagents On Combinatorial Oligonucleotide Arrays," *Nature Biotech.* 15:537-541
- Monia et al. (1996) "Antitumor Activity of a Phosphorothioate Antisense Oligodeoxynucleotide Targeted Against C-raf Kinase," *Nature Med.* 2(6):668-675

- Agrawal (ed.) "Antisense Therapeutics," *Meth. in Mol. Medicine* Preface v, Humana Press, New Jersey (1996)
- Zamecnik, Agrawal (ed.) "Antisense Therapeutics," *Meth. in Mol. Medicine* p. 6, Humana Press, New Jersey (1996)
- Craig et al. (1997) "Patent Strategies in the Antisense Oligonucleotide Based Therapeutic Approach," *Exp. Opin. Ther. Patents* 7(10):1175-1182

A copy of the following reference is currently unavailable; however, Applicant will provide a copy of this reference as soon as possible.

- Kabat and Mayer (eds.), "Experimental Immunochemistry, 2d Edition," p. 135-240, Springfield, IL, CC Thomas (1961).

Furthermore, for the following references, the English abstracts only are provided:

- DE 41 10 085 A1 October 1, 1992
- WO 94/13685 June 23, 1994


This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

A fee for the submission of this Supplemental Information Disclosure Statement is believed to be due in the amount of \$180.00. Please charge the amount of \$180.00 to our Deposit Account No. 08-0219. The Commissioner is hereby authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. 08-0219.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,

HALE AND DORR LLP



Ann-Louise Kerner, Ph.D.
Registration No. 33,523
Attorney for Applicants

October 17, 2001

60 State Street
Boston, MA 02109
(617) 526-6192
(617) 526-5000 (fax)

Form PTO-1449				Docket Number HYZ-050CP2 (47508.446)		Application Number 09/412,947	
SUPPLEMENTAL INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Agrawal			
				Filing Date October 5, 1999		Group Art Unit 1635	
Sheet	1	OF	2				

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,806,463	02/21/89	Goodchild et al.	435	5	
	5,194,428	03/16/93	Agrawal et al.	514	44	
	5,149,797	09/22/92	Pederson et al.	536	27	

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	DE 41 10 085 A1	10/01/92	GERMANY Abstract Only				
	WO 93/13114	07/08/93	WO				
	WO 93/13121	07/08/93	WO				
	WO 93/13740	07/22/93	WO				
	WO 94/02498	02/03/94	WO				
	WO 94/08003	04/14/94	WO				
	WO 94/13685	06/23/94	WO Abstract Only				
	WO 94/26887	11/24/94	WO				
	WO 95/02069	01/19/95	WO				
	WO 95/09236	04/06/95	WO				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
	A1	Kabat and Mayer (eds.), "Experimental Immunochemistry, 2d Edition," p. 135-240, Springfield, IL, CC Thomas (1961)
	A2	Meteliev et al. (1994) "Study of Antisense Oligonucleotide Phosphorothioates Containing Segments of Oligodeoxynucleotides and 2'-O-Methyloligonucleotides," <i>Bioorganic & Medicinal Chem. Lett.</i> 4:2929-2934
	A3	Paterson et al. (1977) "Structural Gene Identification and Mapping by DNA mRNA Hybrid-Arrested Cell-Free Translation," <i>Proc. Natl. Acad. Sci. USA</i> 74:4370-4374
	A4	Stephenson et al. (1978) "Inhibition of Rous Sarcoma Viral RNA Translation By A Specific Oligodeoxyribonucleotide," <i>Proc. Natl. Acad. Sci. USA</i> 75:285-288
	A5	Agrawal et al. (1995) "Modified Oligonucleotides As Therapeutic And Diagnostic Agents," <i>Curr. Opin. Biotech.</i> 6:12-19
	A6	Agrawal et al. (1995) "Pharmacokinetics of Antisense Oligonucleotides," <i>Clin. Pharmacokinet.</i> 28:7-16
	A7	Krieg et al. (1995) "CpG Motifs In Bacterial DNA Trigger Direct B-Cell Activation," <i>Nature</i> 374:546-549
	A8	Kandimalla et al. (1995) "Synthesis and Properties of 2'-O-Methylribonucleotide Methylphosphonate Containing Chimeric Oligonucleotides," <i>Nucleosides and Nucleotides</i> 14:1031-1035

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

